UNLIMITED TURBO BULL - ASTRAZENECA | Market Closed - Euronext Paris 10:00:01 28/06/2024 pm IST | ||
| 3.68 EUR | -1.21% |
|
| Current month | +4.68% | ||
| 1 month | +8.85% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 3.69 | -0.94% |
| 27/24/27 | 3.725 | -4.97% |
| 26/24/26 | 3.92 | +0.77% |
| 25/24/25 | 3.89 | 0.00% |
| 24/24/24 | 3.89 | -0.38% |
Real-time Euronext Paris
Last update June 28, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| 34V8S | |
| ISIN | DE000SH8YA46 |
| Date issued | 20/04/2022 |
| Strike | 9,257 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.11 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.485 € |
|---|---|
| Lowest since issue | 0.535 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
156.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.69%
- Stock Market
- Certificates
- 34V8S Certificat
